A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 16 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 22 Dec 2014 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2016.as per ClinicalTrials.gov
- 23 Dec 2013 Planned end date changed to 1 Jan 2015, as per ClinicalTrials.gov record.